Spontaneous remission in diffuse large cell lymphoma: a case report
| Autor: | Gustavo A. Rivero, A. Frolov, April A. Ewton, N. Mihyawi, J. Snijder |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
T cell
Biopsy Remission Spontaneous Follicular lymphoma lcsh:Medicine Spontaneous remission Case Report 030204 cardiovascular system & hematology T-Lymphocytes Regulatory Virus 03 medical and health sciences 0302 clinical medicine Fatal Outcome Surgical oncology hemic and lymphatic diseases Medicine Humans Retrospective Studies Inflammation Aged 80 and over Spontaneous regression medicine.diagnostic_test business.industry lcsh:R General Medicine Diffuse large B-cell lymphoma medicine.disease Immunity Innate Lymphoma Ageing medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer research Female Lymph Nodes Lymphoma Large B-Cell Diffuse business Tomography X-Ray Computed |
| Zdroj: | Journal of Medical Case Reports Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-7 (2019) |
| ISSN: | 1752-1947 |
| Popis: | Background Spontaneous remission in solid malignancies has been documented. However, spontaneous remission in aggressive diffuse large b cell lymphoma is exceedingly rare. Previous reports of lymphoma remission suggest that not yet fully characterized tumor-intrinsic and microenvironment mechanisms cooperate with spontaneous regression. Case description Here, we report the case of an 88-year-old white woman with diffuse large b cell lymphoma (follicular lymphoma transformed) who achieved morphologic spontaneous remission 3 months after her diagnostic core biopsy. We examined 16 similar cases of diffuse large b cell lymphoma suggesting that spontaneous remission is preferentially observed in elderly patients soon after their biopsy microtrauma, especially if malignancies are Epstein–Barr virus driven and activated B-cell type. Conclusion Our case and reported analysis highlight that anti-tumor adaptive T cell responses are potentially augmented in a subset of patients leading to lymphoma regression. In these patients, it is possible that “primed” innate anti-tumor T cell immunity is enhanced in immunogenic lymphoma subtypes after tissue biopsy. Our case and analysis not only reinforce the role of innate T cell anticancer immunity, but also originates potential proof of concept for investigation of unexplored pathways that could favorably impact T cell therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink